Dowm syndrome clinical features and management in deatil
Reading Document
Medical Text Search
Down syndrome trisomy 21 clinical features physical findings
Medical Text Search
Down syndrome management complications cardiac intellectual disability
Medical Image Search
Down syndrome facial features karyotype
GradeResponse
GradeResponse
GradeResponse
The retrieval was limited, so I'll synthesize a comprehensive answer from my medical knowledge combined with retrieved content.
Down Syndrome (Trisomy 21) — Clinical Features & Management
1. Genetics & Epidemiology
| Feature | Detail |
|---|---|
| Incidence | ~1 in 700 live births (most common chromosomal disorder) |
| Prevalence | Most common genetic cause of intellectual disability |
| Maternal age risk | Increases sharply after age 35 (1:385 at 35 → 1:30 at 45) |
Chromosomal Subtypes
| Type | Frequency | Mechanism |
|---|---|---|
| Free trisomy 21 | ~95% | Nondisjunction during meiosis (usually maternal meiosis I) |
| Robertsonian translocation | ~4% | Chromosome 21 attached to another (usually chr 14); hereditary risk |
| Mosaic trisomy 21 | ~1% | Nondisjunction in early mitosis; milder phenotype |
Key point: Robertsonian translocation does NOT increase with maternal age and may be inherited — parents must be karyotyped to assess recurrence risk.
2. Clinical Features
2.1 Dysmorphic / Physical Features
Craniofacial:
- Flat facial profile (midface hypoplasia)
- Brachycephaly (flat occiput)
- Upward-slanting palpebral fissures
- Epicanthic folds
- Brushfield spots (white/grey speckles on iris periphery)
- Flat nasal bridge, small nose
- Small ears, often low-set
- Protruding tongue (relative macroglossia + small oral cavity)
- Short neck with excess nuchal skin
Limbs & Hands:
- Short stature (adult height ~150 cm men, ~138 cm women)
- Short, broad hands
- Single palmar (Simian) crease
- Clinodactyly (incurved 5th finger)
- Wide gap between 1st and 2nd toes ("sandal gap")
- Hypotonia (generalized, prominent in infancy)
- Joint hypermobility/laxity
Other:
- Low birth weight
- Excess skin at nape of neck in neonates
2.2 Neurodevelopmental Features
| Domain | Finding |
|---|---|
| Intellectual disability | Mild to moderate (IQ typically 35–70); severe in ~10% |
| Speech & language | Expressive > receptive delay; dysarthria common |
| Motor development | Delayed (walking at ~2 years on average) |
| Behavior | Generally sociable, affectionate; may show stubbornness, repetitive behaviors |
| ADHD | Present in ~6–10% |
| Autism Spectrum Disorder | ~5–10%; higher in males |
2.3 Systemic Complications
Cardiovascular (40–50%)
- AVSD (atrioventricular septal defect) — most characteristic; ~40% of cardiac defects
- VSD (~32%)
- ASD (~10%)
- Tetralogy of Fallot (~6%)
- PDA
- Early pulmonary hypertension if unrepaired (Eisenmenger syndrome risk)
Gastrointestinal (5–15%)
- Duodenal atresia ("double bubble" sign on X-ray — nearly pathognomonic)
- Hirschsprung disease (~2%)
- Tracheoesophageal fistula
- Pyloric stenosis
- Imperforate anus
- Celiac disease (~5–7%)
Hematological
- Transient Myeloproliferative Disorder (TMD): ~10% of neonates; usually resolves spontaneously
- Acute Megakaryoblastic Leukemia (AMKL/AML-M7): ~1–2%; risk 150× higher than general population
- ALL: 20× increased risk
- Polycythemia in neonates
Endocrine
- Hypothyroidism (congenital or acquired — Hashimoto's) in ~15–20%
- Diabetes mellitus (type 1 and 2)
- Obesity — very common in older children/adults
Musculoskeletal
- Atlantoaxial instability (~15%): subluxation risk; may cause cord compression
- Hip instability/dislocation
- Patellar instability
- Flat feet (pes planus)
Respiratory
- Obstructive sleep apnea (OSA) — very common (~50–75%)
- Recurrent otitis media with effusion
- Subglottic stenosis
- Increased susceptibility to respiratory infections
Ophthalmological
- Refractive errors (very common — ~70%)
- Strabismus (~30%)
- Nystagmus
- Cataracts (congenital or acquired)
- Keratoconus
Hearing
- Conductive hearing loss (very common — ~50–70%) due to chronic serous otitis media
- Sensorineural hearing loss (~20%)
Neurological
- Seizures (~8–13%)
- Infantile spasms
- Alzheimer's disease: virtually universal neuropathological changes by age 40; clinical dementia in ~50% by age 60 (linked to APP gene on chromosome 21)
Dermatological
- Dry skin, xerosis
- Alopecia areata
- Folliculitis
3. Prenatal Diagnosis
Screening
| Test | Timing | Markers |
|---|---|---|
| First trimester combined | 11–13+6 weeks | Nuchal translucency (NT) + β-hCG + PAPP-A |
| Second trimester quad screen | 15–20 weeks | AFP↓, β-hCG↑, uE3↓, inhibin A↑ |
| Cell-free DNA (cfDNA/NIPT) | ≥10 weeks | Most sensitive/specific (DR ~99%, FPR <0.1%) |
Diagnostic (Confirmatory)
- Chorionic villus sampling (CVS): 10–13 weeks
- Amniocentesis: 15–20 weeks
- Karyotype or chromosomal microarray on obtained cells
4. Management
Down syndrome requires multidisciplinary, lifelong care. Management is organized below by domain and age.
4.1 Neonatal Period
- Cardiac echo: all newborns — ~50% have CHD, often asymptomatic at birth
- Feeding support: for hypotonia and poor suck
- Thyroid function (TSH, T4) at birth and at 6 months
- Hearing screen (OAE/ABR)
- Ophthalmology referral
- Karyotype confirmation
- Genetic counseling for family
- Early intervention referral
4.2 Cardiovascular Management
- Echocardiogram in all neonates
- Surgical repair of CHD (AVSD repair typically at 3–6 months before pulmonary hypertension establishes)
- Cardiology follow-up lifelong
- Endocarditis prophylaxis per guidelines
4.3 Neurodevelopmental Interventions
| Therapy | Target | Timing |
|---|---|---|
| Early intervention | Global development | Birth to 3 years |
| Speech-language therapy | Language, feeding, articulation | As soon as delay identified |
| Occupational therapy | Fine motor, ADLs | Early childhood onward |
| Physical therapy | Gross motor, hypotonia | Infancy onward |
| Special education / IEP | Cognitive, academic | School age |
| Augmentative & alternative communication (AAC) | Non-verbal or limited verbal children | As needed |
- Inclusion in mainstream education with appropriate support improves outcomes
- Behavioral therapy for ADHD/ASD comorbidities
4.4 Endocrine & Metabolic
- Thyroid screening: at birth, 6 months, 12 months, then annually
- Treatment with levothyroxine for hypothyroidism
- Dietary counseling and physical activity for obesity prevention/management
- Bone density monitoring in adults
4.5 Atlantoaxial Instability
- Clinical surveillance for symptoms (neck pain, weakness, gait change, torticollis)
- Cervical spine X-rays (flexion/extension views) in symptomatic patients or before contact sports/surgery
- Atlanto-dens interval (ADI) >4.5 mm = abnormal; >7–10 mm = surgical concern
- Restrict contact sports/gymnastics if symptomatic instability
- Neurosurgical referral for myelopathy
4.6 Hearing & ENT
- Hearing screen at birth and annual audiological assessment
- Myringotomy + grommets (PE tubes) for recurrent serous otitis media
- Hearing aids when indicated
- Adenotonsillectomy for OSA (first-line surgical treatment)
- Polysomnography recommended for all children with Down syndrome (~2–4 years)
4.7 Ophthalmology
- Annual ophthalmology review from infancy
- Glasses for refractive errors
- Patching/surgery for strabismus
- Slit lamp for cataracts/keratoconus
4.8 Hematological Surveillance
| Condition | Action |
|---|---|
| TMD (neonatal) | Usually observe; low-dose cytarabine for symptomatic/life-threatening cases |
| AML/ALL | Prompt oncology referral; Down syndrome-associated leukemia often MORE responsive to chemotherapy (favorable prognosis for AMKL) |
| Polycythemia | Partial exchange transfusion if symptomatic |
4.9 Gastrointestinal
- Surgical correction of duodenal atresia, Hirschsprung disease, TEF in neonatal period
- Screen for celiac disease (anti-tissue transglutaminase IgA + total IgA) at ~2–3 years and if symptomatic
- Constipation management (common due to hypotonia + Hirschsprung)
4.10 Alzheimer's Disease & Adult Neurological Care
- Virtually all adults with Down syndrome develop Alzheimer's pathology by age 40
- Clinical dementia onset typically in 5th–6th decade
- Baseline cognitive and adaptive functioning assessment at ~30 years
- Annual monitoring for cognitive decline from age 40
- Cholinesterase inhibitors (donepezil) may offer modest symptomatic benefit
- Support for caregivers and advance care planning
4.11 Mental Health
- Screen for depression, anxiety, ADHD, ASD
- Psychotherapy, behavioral interventions
- Pharmacotherapy when needed (SSRIs for depression/anxiety; stimulants for ADHD with monitoring)
5. Health Surveillance Summary (by Age)
| Age | Key Checks |
|---|---|
| Neonate | Echo, TSH, hearing, karyotype, feeding assessment, ophthalmology |
| 6 months | TSH, developmental review, audiology, ophthalmology |
| 1–2 years | TSH, audiology, ophthalmology, celiac screen, cervical spine if concerns |
| 3–5 years | Polysomnography (OSA screen), ENT, development |
| School age | Annual TSH, audiology, ophthalmology, behavior/mental health, BMI |
| Adolescence | Pubertal development, contraception counseling, vocational planning |
| Adults (30+) | Baseline cognitive assessment, annual TSH, bone density, Alzheimer's surveillance |
6. Prognosis & Quality of Life
- Median life expectancy has improved dramatically: ~60 years today (vs. 25 years in 1983)
- Many adults live semi-independently or with supported living
- Meaningful employment is achievable with appropriate vocational support
- Recurrence risk: ~1% for free trisomy 21 + age-related risk; up to 100% for certain translocations (e.g., 21;21 translocation parent)
Key References: Nelson Textbook of Pediatrics | Smith's Recognizable Patterns of Human Malformation | AAP Health Supervision Guidelines for Children with Down Syndrome (2022) | GeneReviews — Trisomy 21
This is a shared conversation. Sign in to Orris to start your own chat.